Groin recurrence · patients with Early Vulvar Cancer
Primary Groin Radiotherapy showed no clear difference in groin recurrence compared with primary Groin Surgery (low certainty).
1 finding from 1 review
Disease specific mortality · patients with Early Vulvar Cancer
Primary Groin Radiotherapy showed no clear difference in disease specific mortality compared with primary Groin Surgery (low certainty).
1 finding from 1 review
Rate of spontaneous voiding recovery 1 week after surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time after surgery to post‐void residual volume of urine ≤ 50 mL (days)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (acute complication after surgery)
It is very uncertain whether suprapubic catheterisation changes adverse events (acute complication after surgery) compared with intermittent self‐catheterisation (very low certainty).
1 finding from 1 review
Post‐void residual urine volume (mL) at 1 month after surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Urinary tract infection
It is very uncertain whether suprapubic catheterisation changes urinary tract infections in the first month after surgery compared with intermittent self‐catheterisation (very low certainty).
1 finding from 1 review
Time after surgery to post‐void residual volume of urine ≤ 50 mL (days)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Post‐void residual urine volume (mL) at 1 month after surgery
1 finding from 1 review
Urinary tract infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Rate of spontaneous voiding recovery 1 week after surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (survival until death from all causes) · adult women diagnosed with early stage (I to IIa) endometrial cancer undergoing surgery as primary treatment.
Laparoscopy showed no clear difference in overall survival (survival until death from all causes) compared with laparotomy (moderate certainty).
1 finding from 1 review
Recurrence‐free survival · adult women diagnosed with early stage (I to IIa) endometrial cancer undergoing surgery as primary treatment.
Laparoscopy showed no clear difference in recurrence free survival compared with laparotomy (moderate certainty).
1 finding from 1 review
Serious adverse events (range of outcomes) · adult women diagnosed with early stage (I to IIa) endometrial cancer undergoing surgery as primary treatment.
Laparoscopy showed no clear difference in serious adverse events (range of outcomes) compared with laparotomy (low certainty).
1 finding from 1 review
Intervention not reported
Death within 5 years · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA)
The intervention showed no clear difference in death within 5 years (moderate certainty).
1 finding from 1 review
Intervention not reported
Disease progression within 5 years · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA)
The intervention probably leads to lower disease progression within 5 years (moderate certainty).
1 finding from 1 review
Intervention not reported
Haematological adverse events (grade 3 or 4) · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA)
The intervention showed no clear difference in haematological adverse events (grade 3 or 4) (moderate certainty).
1 finding from 1 review
Intervention not reported
Gastrointestinal adverse events (grade 3 or 4) · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA)
The intervention showed no clear difference in gastrointestinal adverse events (grade 3 or 4) (moderate certainty).
1 finding from 1 review
Intervention not reported
Genitourinary adverse events (grade 3 or 4) · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA)
The intervention showed no clear difference in genitourinary adverse events (grade 3 or 4) (moderate certainty).
1 finding from 1 review
Intervention not reported
Overall 5‐year survival1 · women with stage I/II epithelial ovarian cancer
1 finding from 1 review
no estimate extracted
1008 participants
High